Loading...
XSTO
BINV
Market cap260mUSD
Jun 09, Last price  
37.25SEK
1D
0.79%
1Q
41.37%
Jan 2017
-49.34%
IPO
-96.05%
Name

BioInvent International AB

Chart & Performance

D1W1MN
P/E
—
P/S
54.85
EPS
—
Div Yield, %
—
Shrs. gr., 5y
28.89%
Rev. gr., 5y
-13.77%
Revenues
45m
-37.47%
28,198,00050,829,000143,437,000252,138,00080,659,00082,866,000124,649,00042,946,00081,713,00046,932,00015,925,00071,284,00045,014,00038,548,00093,740,000147,372,00019,384,000326,126,00071,461,00044,686,000
Net income
-429m
L+29.99%
-139,862,000-108,833,000-16,093,00016,251,000-176,661,000-128,400,000-67,053,000-187,845,000-18,039,000-53,985,000-90,681,000-62,587,000-100,528,000-123,163,000-139,115,000-76,669,000-278,961,000-34,085,000-330,304,000-429,375,000
CFO
-380m
L+11.35%
-105,479,000-101,228,00012,627,00043,726,000-127,143,000-117,700,000-55,454,000-170,381,000-54,652,000-76,028,000-72,573,000-72,049,000-75,876,000-141,394,000-125,427,000-62,622,000-245,843,000-41,227,000-341,691,000-380,469,000
Earnings
Aug 27, 2025

Profile

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
URL
https://www.bioinvent.com/
IPO date
Jun 12, 2001
Employees
103
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
44,686
-37.47%
71,461
-78.09%
326,126
1,582.45%
Cost of revenue
516,035
442,040
376,679
Unusual Expense (Income)
NOPBT
(471,349)
(370,579)
(50,553)
NOPBT Margin
Operating Taxes
135
204
(8,418)
Tax Rate
NOPAT
(471,484)
(370,783)
(42,135)
Net income
(429,375)
29.99%
(330,304)
869.06%
(34,085)
-87.78%
Dividends
Dividend yield
Proceeds from repurchase of equity
30,959
279,849
BB yield
-2.48%
-14.19%
Debt
Debt current
9,198
8,709
8,190
Long-term debt
25,628
37,779
45,736
Deferred revenue
Other long-term liabilities
Net debt
(832,333)
(427,312)
(1,037,261)
Cash flow
Cash from operating activities
(380,469)
(341,691)
(41,227)
CAPEX
(10,034)
(13,304)
(12,377)
Cash from investing activities
564,346
59,681
(628,848)
Cash from financing activities
(8,455)
23,139
273,487
FCF
(464,843)
(371,434)
(45,063)
Balance
Cash
867,159
1,068,699
1,017,481
Long term investments
(594,899)
73,706
Excess cash
864,925
470,227
1,074,881
Stockholders' equity
(2,449,529)
(2,122,342)
Invested Capital
903,228
3,782,500
3,755,427
ROIC
ROCE
EV
Common stock shares outstanding
65,683
65,798
61,521
Price
38.50
103.06%
18.96
-40.84%
32.05
-30.63%
Market cap
2,528,814
102.71%
1,247,523
-36.73%
1,971,748
-21.20%
EV
1,696,481
820,211
934,487
EBITDA
(452,049)
(353,824)
(35,829)
EV/EBITDA
Interest
638
650
Interest/NOPBT